In a new study published in JAMA Network Open, researchers at Thomas Jefferson University have developed a novel screening tool to measure digital health readiness, which will be critical in addressing barriers to telehealth adoption among diverse patient populations.
EC approves Pfizer’s Talzenna combo for prostate cancer treatment
Share this article The EC approval extends use of Pfizer’s Talzenna combo to all 27 member states in the EU plus Liechtenstein, Iceland and Norway.